Compare HNVR & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNVR | KRRO |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 150.0M |
| IPO Year | 2022 | 2019 |
| Metric | HNVR | KRRO |
|---|---|---|
| Price | $23.23 | $11.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $24.50 | ★ $34.80 |
| AVG Volume (30 Days) | 9.3K | ★ 76.2K |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | N/A | ★ $6,392,000.00 |
| Revenue This Year | $35.49 | N/A |
| Revenue Next Year | $8.61 | N/A |
| P/E Ratio | $23.31 | ★ N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $19.91 | $5.20 |
| 52 Week High | $24.49 | $55.89 |
| Indicator | HNVR | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 55.80 | 41.78 |
| Support Level | $22.93 | $10.81 |
| Resistance Level | $24.38 | $14.52 |
| Average True Range (ATR) | 0.42 | 0.83 |
| MACD | -0.02 | -0.21 |
| Stochastic Oscillator | 41.86 | 8.30 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.